Phase 3 N=89 Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis
Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=4 Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis · Lymphangiomyomas · Pleural Effusions
Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants
Phase 2 N=17 Letrozole for Lymphangioleiomyomatosis
Lymphangioleiomyomatosis
Primary: Rate of Change in Forced Expiratory Volume in 1 Second in ml/Month — 1.04; 1.66 milliliters per month — p=0.4
Phase 2 N=33 Discovery of Sirolimus Sensitive Biomarkers in Blood
Lymphangioleiomyomatosis
Primary: Number of Sirolimus-Sensitive Plasma Protein Biomarkers in Lymphangioleiomyomatosis (LAM) Participants — 662 plasma proteins
Phase 2 N=16 LAM Pilot Study With Imatinib Mesylate
Lymphangioleiomyomatosis
Primary: Serum VEGF-D — 0.05; 0.07 Log transformed VEGF-D change pg/dL
Phase 1 N=13 Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis
Primary: Safety of Combination Therapy With Sirolimus and Hydroxychloroquine in LAM Patients — 2.27; 1.11; 0; 1.11 Percentage of adverse events
Phase 2 N=24 A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Lymphangioleiomyomatosis
Primary: Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations — -464.3; -1113.2; -1771.7 pg/mL
Phase 3 N=118 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Tuberous Sclerosis Complex (TSC) · Lymphangioleiomyomatosis (LAM)
Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001
Phase 2 N=25 Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
Lymphangioleiomyomatosis
Primary: Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on…
Phase 2 N=36 RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Phase 2 N=12 COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Lymphangioleiomyomatosis (LAM)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 11 Participants
Phase 2 N=10 Safety of Simvastatin in LAM and TSC
Lymphangioleiomyomatosis · Tuberous Sclerosis Complex
Primary: Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients — 0 participants
Phase 2 N=94 Treatment and Natural History Study of Lymphomatoid Granulomatosis
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Phase 4 N=40 Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Renal Angiomyolipoma
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 39; 6; 2 Participants
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
Phase 2 N=124 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Phase 2 N=12 Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformation
Primary: Incidence of Treatment-Emergent Adverse Events — 9; 2; 6; 2 participants
Phase 2 N=275 OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
Phase 2 N=18 Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Phase 2 N=7 A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Lymphangioma
Primary: Change in Volume of Lymphatic Malformation — 3.7; -4.3; -1.0; -31.7 percentage of volume change
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=19 Sildenafil for the Treatment of Lymphatic Malformations
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=47 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=16 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume